Comparative Efficacy, Tolerability With RP2D of Belzutifan in LITESPARK-013 Trial for ccRCC
Results unveiled at the 2023 International Kidney Cancer Symposium revealed that patients with advanced clear cell renal cell carcinoma in the 200-mg dose group achieved an overall response rate of 23.1% based on blinded independent central review.
Sacituzumab Govitecan With Enfortumab Vedotin Produces Early Responses in mUC
The combination of sacituzumab govitecan-hziy and enfortumab vedotin-ejfv showed early responses in patients with treatment-resistant metastatic urothelial cancer.
Cilta-Cel Achieved PFS Prolongation in Patients With Myeloma and Poor Prognosis
The observed benefits of ciltacabtagene autoleucel in patients with multiple myeloma and poor prognostic features are consistent with the overall the population of CARTITUDE-4.
Cilta-Cel Shows PFS Benefit in Patients With Multiple Myeloma and Poor Prognostic Features
In the phase 3 CARTITUDE-4 trial, ciltacabtagene autoleucel was shown to be effective when used in patients with multiple myeloma exhibiting poor prognostic features.
Upfront Atezolizumab Plus Bevacizumab and Chemo Shows No Significant PFS Benefit in NSCLC
The phase 3 IMpower151 study has missed it primary end point of progression-free survival.
Combination of Dabrafenib, Trametinib, and Navitoclax Shows Promise in Metastatic Melanoma
While the phase 2 CTEP-P9466 trial met its complete response end point, the trial missed its other co-primary end points in patients with BRAF V600–mutant metastatic melanoma.
Use of the Investigational Therapy Nirogacestat Reduces Pain in Patients With Desmoid Tumors
New findings with the gamma secretase inhibitor nirogacestat show pain reduction for patients with desmoid tumors.
2 Clarke Drive Cranbury, NJ 08512